Persistent URL of this record https://hdl.handle.net/1887/3184771
Documents
-
- Download
- jco.19.01814_oe1oe
- Publisher's Version
-
open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: TRAP study
- All authors
- Stroes, C.I.; Schokker, S.; Creemers, A.; Molenaar, R.J.; Hulshof, M.C.C.M.; Woude, S.O. van der; Bennink, R.J.; Mathot, R.A.A.; Krishnadath, K.K.; Punt, C.J.A.; Verhoeven, R.H.A.; Oijen, M.G.H. van; Creemers, G.J.; Nieuwenhuijzen, G.A.P.; Sangen, M.J.C. van der; Beerepoot, L.V.; Heisterkamp, J.; M. los; Slingerland, M.; Cats, A.; Hospers, G.A.P.; Bijlsma, M.F.; Henegouwen, M.I.V.; Meijer, S.L.; Laarhoven, H.W.M. van
- Date
- 2020-02-10
- Journal
- Journal of Clinical Oncology
- Volume
- 38
- Issue
- 5
- Pages
- 462 - 471